Tag: HFSA

Kestra Showcases Cardiac Recovery System Platform at HFSA 2025, Redefining Sudden Cardiac Arrest Risk Management

KIRKLAND, Wash., Sept. 25, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced its debut at the 2025 Heart Failure Society of America (HFSA) Annual Scientific Meeting, September 26–29 in Minneapolis, Minnesota. At booth #920, Kestra will feature its Cardiac Recovery System® (CRS) platform, anchored by the ASSURE® Wearable Cardioverter Defibrillator. The CRS platform closes the critical gap in sudden cardiac death protection by pairing protection with actionable insights that support confident care during the high-risk early phase of heart failure recovery. Attendees can explore the CRS platform through an immersive booth experience and hands-on demonstrations that highlight how it empowers clinicians, strengthens patient–provider connections, and supports recovery for vulnerable patients. “Our presence at HFSA underscores Kestra’s commitment to advancing care for heart failure patients,” said Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies. “The Cardiac Recovery System platform redefines how sudden cardiac arrest risk is managed, equipping clinicians with technologies and insights that protect patients and strengthen recovery support.” Kestra will also participate in the Devices in Heart Failure Meeting on Friday, September 26, where attendees can see the ASSURE system up close and learn how it integrates into clinical workflows to support guideline-directed medical therapy. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com. CONTACT: Media contact
Rhiannon Pickus
rhiannon.pickus@kestramedical.com

Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com

Heart Failure Society of America Celebrates 30 Years with Lineup of Visionary Leaders at Annual Scientific Meeting 2025

Saturday Plenary to Spotlight Innovations in Heart Failure Research, AI, and Future Care Models WASHINGTON, July 24, 2025 /PRNewswire/ — The Heart Failure Society of America (HFSA) is marking 30 years of leadership in heart failure care with a dynamic celebration at the HFSA Annual…

First Cohort of Heart Failure Specialists to Earn Heart Failure Certification (HF-Cert™) Announced by Heart Failure Society of America

ROCKVILLE, Md., June 7, 2023 /PRNewswire/ — The Heart Failure Society of America (HFSA) today announced the first cohort of heart failure (HF) providers to earn the Heart Failure Certification (HF-Cert). The multi-disciplinary certification recognizes HF providers who have demonstrated advanced-level knowledge and skill to provide competent heart failure services in the United […]

Joint Guideline on Acute Mechanical Circulatory Support Released by the Heart Failure Society of America and the International Society for Heart and Lung Transplantation

ROCKVILLE, Md., Feb. 6, 2023 /PRNewswire/ — A new joint guideline published today by the Heart Failure Society of America (HFSA) and the International Society for Heart and Lung Transplantation (ISHLT) addresses the growing availability and use of acute or temporary mechanical support devices. The joint guideline provides critical recommendations and protocols for the […]

Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member

Oak Ridge, TN, Jan. 19, 2023 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces joining the Heart Failure Society of America (HFSA) as a corporate member to collaborate and deepen engagement with leaders in the field of heart failure. “The HFSA is the premier […]

BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting

Clinical Leadership and Management Call Scheduled for Wednesday, October 5, 2022, at 8:55am Eastern Time SUNNYVALE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces data from its FDA designated Breakthrough CardiAMP® Cell Therapy […]

Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting

Statistically Significant Reduction in CV Mortality and HF Rehospitalizations as Compared to IV Diuretics at 30 and 90 Days MINNEAPOLIS, Oct. 03, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the results of the AVOID-HF […]

ImpediMed Announces Two Posters at Heart Failure Society of America Annual Scientific Meeting That Demonstrate Utility of SOZO® Digital Health Platform for Heart Failure Patients

CARLSBAD, Calif. and BRISBANE, Australia, Sept. 30, 2022 /PRNewswire/ — ImpediMed Limited (ASX: IPD), a global medical technology company using bioimpedance spectroscopy (BIS) to generate powerful data to maximize patient health, today announced two poster presentations at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, which is taking place Sept. 30 to Oct. […]

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

 — Pediatric efficacy data for both patients show initial improvements across clinical, functional and biomarker endpoints with six to nine months of follow-up; positive results including protein expression obtained at three and six months consistent with adult cohorts at similar timeframe— — Results demonstrate sustained clinical benefit across all parameters in adult […]